Browse > Article
http://dx.doi.org/10.3345/kjp.2009.52.11.1249

Economic evaluation of a weekly administration of a sustained-release injection of recombinant human growth hormone for the treatment of children with growth hormone deficiency  

Kang, Hye-Young (Graduate School of Public Health, Institute of Health Services Research, Yonsei University)
Kim, Duk Hee (Department of Pediatrics, Severance Children's Hospital, Yonsei University)
Yang, Sei-Won (Department of Pediatrics, College of Medicine, Seoul National University)
Kim, Yoon-Nam (Graduate School of Public Health, Yonsei University)
Kim, Miseon (Graduate School of Public Health, Yonsei University)
Publication Information
Clinical and Experimental Pediatrics / v.52, no.11, 2009 , pp. 1249-1259 More about this Journal
Abstract
Purpose:From a societal perspective, we evaluated the cost-effectiveness of a novel sustained-release injection of recombinant human growth hormone (GH) administered on a weekly basis compared with that of the present daily GH injection for the treatment of children with GH deficiency. Methods:Health-related utility for GH therapy was measured based on the visual analogue scale. During July 2008, caregivers of 149 children receiving GH therapy form 2 study sites participated in a web-based questionnaire survey. The survey required the caregivers to rate their current subjective utility with daily GH injections or expected utility of weekly GH injections. Because there was no difference in the costs of the daily and weekly therapies, for the purposes of this study, only drug acquisition costs were considered. Results:Switching from daily to weekly injection of GH increased the utility from 0.584 to 0.784 and incurred an extra cost of 4,060,811 Korean won (KW) per year. The incremental cost-utility ratio (ICUR) for a base case was 20,305,055 KW per quality-adjusted life year (QALY) gained. Scenario analyses showed that the ICUR ranged from 15,751,198 to 25,489,929 KW per QALY. Conclusion:The ICUR for a base case and worst case scenario analyses ranged from 0.85 to 1.37-times per capita gross domestic product of Korea, which is considered to be within the generally accepted willingness-to-pay threshold. Thus, it is concluded that switching from daily to weekly injection of GH would be cost-effective.
Keywords
Cost, Cost effectiveness; Growth hormone; Quality of life; Recombinant growth hormone; Utility;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Yang SW. Management of children with short stature. J Korean Endocr Soc 2003;18:561-70
2 Silverman BL, Blethen SL, Reiter EO, Attie KM, Neuwirth RB, Ford KM. A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency. J Pediatr Endocrinol Metab 2002;15 Suppl 2:715-22
3 Chiarelli F, Veimo D, Tauber M, Langham S, Dumas H, Johansson L, et al. Observations of non-adherence to recombinant human growth hormone therapy in clinical practice. Clin Ther 2008;30:307-16   DOI   ScienceOn
4 Jnsson B, Mavros P, Gerth WC, Kong SX, Eichler H. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-28   DOI   ScienceOn
5 Torrance GW, SiggelJE, Luce BR. Framing and designing the cost-effectiveness analysis. In: Gold MR, Seigel JE, Ressell LB, Weinstein MC, eds., Cost-effectiveness in health and medicine. Oxford, New York. Oxford University Press, 1996: 54
6 Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value in Health 2004;7:518-28   DOI   ScienceOn
7 Grumbach MM. Growth hormone therapy and the short end of the stick. N Eng J Med 1988;319:238-41   DOI   PUBMED   ScienceOn
8 Lim SJ, Kang HY, Kang YJ, Lee BS, Park HM, Shin DH. Measuring utility for menopausal systems based on time trade-off and visual analogue scale methods. Korean J of Health Policy & Administration 2007;17:113-33   DOI   ScienceOn
9 Ferris DG, Miller MD. Measurement of subjective phenomena in primary care research: the Visual Analogue Scale. The Fam Pract Res J 1993;13:15-24   PUBMED
10 Khan ZM, Keskinaslan A, Benedict A, Brixner D, Muszbek N. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract 2008;62:338-51   DOI   PUBMED   ScienceOn
11 Bakker B, Rosenfeld RG. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 2008;14:143-54   DOI   ScienceOn
12 Philip BK. Parametric statistics for evaluation of the visual analog scale. Anesth Analg 1990;71:710   DOI   ScienceOn
13 Lee BC, Ko CW, Kim DH, Yang SW, Yoo HW, Chung WY. Clinical effects of E cole derived authentic recombinant human growth hormone(DA-3002) in children with growth hormone deficiency. J Korean Endocr Soc 1998;13:526-35
14 Kim YI, Kim ES, Son JG. Human growth hormone. Seoul: Korea Institute of Science and Technology Information, 2002
15 Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Ch 6. Cost-Utility Analysis. In: Methods for the economic evaluation of health care programmes. 3rd ed. New York. Oxford University Press, 2005b:151-3
16 Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Ch 6. Cost-Utility Analysis. In: Methods for the economic evaluation of health care programmes. 3rd ed. New York. Oxford University Press, 2005a:147
17 LG Life Science. An open-label, active controlled, randomized, parallel-group, multi-centre study to assess efficacy and safety after 6 months-administration of SR-hGH (sustained-release human growth hormone) 0.5 mg/kg/wk and Eutropin inj.(immediate-release human growth hormone) 0.21 mg/kg/wk to improve the growth failure in pre- pubertal children with growth hormone deficiency. 2007
18 World Health Organization. Choosing interventions that are cost effective (WHO-CHOICE). available at: http://www. who.int/choice/costs/CER_thresholds/en/index.html. accessed on Dec. 18, 2008
19 Won JK, Markowski DJ, Sclar DA, Skaer TL. Utility of a sustained-release formulation for antihypertensive therapy. J Hum Hypertens 1993;7:519-22   PUBMED   ScienceOn